Zhongjun Xia

2.0k total citations
76 papers, 1.3k citations indexed

About

Zhongjun Xia is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Zhongjun Xia has authored 76 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 38 papers in Pathology and Forensic Medicine and 20 papers in Molecular Biology. Recurrent topics in Zhongjun Xia's work include Lymphoma Diagnosis and Treatment (33 papers), Multiple Myeloma Research and Treatments (16 papers) and Viral-associated cancers and disorders (16 papers). Zhongjun Xia is often cited by papers focused on Lymphoma Diagnosis and Treatment (33 papers), Multiple Myeloma Research and Treatments (16 papers) and Viral-associated cancers and disorders (16 papers). Zhongjun Xia collaborates with scholars based in China, United States and United Kingdom. Zhongjun Xia's co-authors include Liang Wang, Jiewen Peng, Kefeng Wang, Dongying Liu, Yunfei Xia, Zhi‐Hui Wang, Yue Lu, Qingqing Cai, Huiqiang Huang and Wenqi Jiang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Zhongjun Xia

67 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhongjun Xia China 21 793 492 327 277 194 76 1.3k
Vera Schellerer Germany 20 550 0.7× 210 0.4× 142 0.4× 95 0.3× 76 0.4× 60 1.1k
Fengchun Zhang China 20 225 0.3× 198 0.4× 307 0.9× 215 0.8× 47 0.2× 68 1.3k
Eva Honsová Czechia 19 177 0.2× 154 0.3× 211 0.6× 170 0.6× 141 0.7× 73 1.3k
Po‐Min Chen Taiwan 17 461 0.6× 218 0.4× 88 0.3× 102 0.4× 52 0.3× 80 1.2k
Jeffrey S. Wasser United States 20 587 0.7× 251 0.5× 385 1.2× 231 0.8× 30 0.2× 48 2.0k
Ryo Wada Japan 20 437 0.6× 271 0.6× 68 0.2× 194 0.7× 70 0.4× 140 1.2k
Renata Zaucha Poland 16 455 0.6× 133 0.3× 147 0.4× 105 0.4× 24 0.1× 54 1.1k
Anuhya Kommalapati United States 18 603 0.8× 133 0.3× 66 0.2× 126 0.5× 71 0.4× 63 1.1k
Berksoy Şahin Türkiye 17 322 0.4× 177 0.4× 58 0.2× 169 0.6× 34 0.2× 59 840
Yoon Dae Han South Korea 19 774 1.0× 177 0.4× 240 0.7× 65 0.2× 49 0.3× 90 1.2k

Countries citing papers authored by Zhongjun Xia

Since Specialization
Citations

This map shows the geographic impact of Zhongjun Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhongjun Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhongjun Xia more than expected).

Fields of papers citing papers by Zhongjun Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhongjun Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhongjun Xia. The network helps show where Zhongjun Xia may publish in the future.

Co-authorship network of co-authors of Zhongjun Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Zhongjun Xia. A scholar is included among the top collaborators of Zhongjun Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhongjun Xia. Zhongjun Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Weiling, Yiwen Bu, Min Zeng, et al.. (2025). Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study. Hematological Oncology. 43(4). e70112–e70112.
2.
Yin, Xixi, et al.. (2024). Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma. Cancer Medicine. 13(11). e7347–e7347. 1 indexed citations
3.
Liu, Panpan, Kefeng Wang, Jianan Li, et al.. (2023). Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica. 109(2). 479–492. 4 indexed citations
4.
Chen, Wuyi, et al.. (2022). 3D Quality Evaluation of Rock Mass in Urban Underground Space Based on Improved Fuzzy Analytic Hierarchy Process. KSCE Journal of Civil Engineering. 26(11). 4829–4839. 9 indexed citations
5.
Cai, Jun, Xiao‐Peng Tian, Shu‐Yun Ma, et al.. (2021). A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. British Journal of Cancer. 125(3). 402–412. 11 indexed citations
6.
Zhou, Qian, Tong Yang, Jin Liu, et al.. (2021). Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Molecular Medicine. 14(1). e14502–e14502. 42 indexed citations
7.
Tian, Xiao‐Peng, Jun Cai, Shu‐Yun Ma, et al.. (2020). BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma. Cancer Communications. 40(6). 245–259. 19 indexed citations
8.
9.
Li, Qing, Xiuyu Cai, Xiaoqin Chen, et al.. (2019). Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. International Journal of Hematology. 110(4). 458–465. 1 indexed citations
10.
Chen, Zhen, Yifan Chen, Meng Xu, et al.. (2016). Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo , and Ex Vivo. Molecular Cancer Therapeutics. 15(8). 1845–1858. 45 indexed citations
11.
12.
Zhang, Jing, Wei Jiang, Weida Wang, et al.. (2015). Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma. Asian Pacific Journal of Cancer Prevention. 16(11). 4515–4520. 2 indexed citations
13.
Xia, Zhongjun, et al.. (2015). CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-кB and suppressing the P38 MAPK signaling pathway. Experimental and Molecular Pathology. 100(2). 353–360. 18 indexed citations
14.
15.
Wang, Hua, Pengfei Li, Liang Wang, et al.. (2015). High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type. Annals of Hematology. 94(9). 1535–1544. 24 indexed citations
16.
17.
Lin, Gui‐Nan, Xiaomei Jiang, Jiewen Peng, et al.. (2014). Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy. Asian Pacific Journal of Cancer Prevention. 15(15). 6387–6390. 8 indexed citations
18.
Cai, Qingqing, Xiaolin Luo, Guanrong Zhang, et al.. (2014). New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Annals of Hematology. 93(9). 1541–1549. 20 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vera Schellerer Breakdown of academic impact, for papers by Fengchun Zhang Breakdown of academic impact, for papers by Eva Honsová Breakdown of academic impact, for papers by Po‐Min Chen Breakdown of academic impact, for papers by Jeffrey S. Wasser Breakdown of academic impact, for papers by Ryo Wada Breakdown of academic impact, for papers by Renata Zaucha Breakdown of academic impact, for papers by Anuhya Kommalapati Breakdown of academic impact, for papers by Berksoy Şahin Breakdown of academic impact, for papers by Yoon Dae Han
Rankless by CCL
2026